मलाशय का कैंसर (Rectal cancer)
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
कहाँ जाना है
भारत में 5 अस्पताल इस ट्रायल के लिए मरीज़ों को ले रहे हैं।
रजिस्ट्री समरी (तकनीकी)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type…
Sponsor: Janssen Research & Development, LLC
ClinicalTrials.gov पर NCT06662786
रजिस्ट्री में आखिरी बार 25 Sep 2026 को अपडेट किया गया · हमने 20 Oct 2026 को पढ़ा